None of these studies should be interpreted as recommending BPC-157 for human use, treatment, or any clinical purpose
Dose selection for toxicity studies: a protocol for determining the maximum repeatable dose
Qsymia (phentermine-topiramate) is not licensed for use in the UK by the MHRA Wegovy (semaglutide) is a GLP-1 receptor agonist licensed in the UK and should not be combined with other weight management products according to its Summary of Product Characteristics No clinical trials have investigated the safety or efficacy of combining these two medications Potential risks include cardiovascular effects, amplified gastrointestinal side effects, and central nervous system disturbances UK guidance from NICE recommends single-agent pharmacotherapy optimised within specialist weight management services Sequential therapy or bariatric surgery referral are evidence-based alternatives for patients not responding to single-agent treatment Table of Contents Understanding Qsymia and Wegovy: Different Mechanisms for Weight Loss Can You Take Qsymia and Wegovy Together
Data collection procedure After informed written consent, patients were enrolled with clinical information about the sociodemographic profile (i.e., age, sex, and educational status), anthropometric information (i.e., height, weight, and BMI), disease duration, other comorbidities, ongoing medication, and biochemical information (i.e., HbA1c, blood glucose profile, serum creatinine, eGFR, and fasting lipid profile)
